Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers

Completed · Phase 4

Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)

In brief

About 1 million individuals in the US have a prescription for supplemental oxygen (O2). Using O2 can prolong life and increase quality of life. Patients often do not use their oxygen as prescribed, which means that they are not benefiting as much as they could be from this therapy. The purpose of this study is to evaluate whether a PEer-Led O2 Infoline for patients and CAregivers (PELICAN) will increase adherence to supplemental oxygen prescription and improve health in patients with chronic obstructive pulmonary disease (COPD).

Key facts

Study ID

NCT02098369

Run by

University of Illinois at Chicago

People needed

444

Starts

2015-04-01

Expected to finish

2016-10-01

Last updated by the study team

2018-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older.
• Physician diagnosis of COPD
• Physician prescription for home O2 for 24hrs/day, 7 days/week
• Willing to use home O2.
• Working telephone number.

You may not qualify if…

• Unable to read and speak English.
• Discharge to home hospice or expected survival less than 6 months.

Where it is running

• Apria Healthcare — Lake Forest, California, United States
• Los Angeles Biomedical Research Institute — Torrance, California, United States
• National Jewish Health — Denver, Colorado, United States
• AlphaNet — Miami, Florida, United States
• COPD Foundation — Miami, Florida, United States
• University of Illinois Hospital — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.